Effect of anticovid plasma on COVID-19 among patients in intensive care unit of COVID hospital
The spread of the SARS-CoV-2 virus and the increased mortality caused by it has led to the search and evaluation of available methods of drug therapy for patients, especially those who are in intensive care units of COVID hospitals. A feature of the course of coronavirus infection is its unpredictable nature and severity. In this regard, it became necessary to use targeted and powerful means of pathogenetic therapy. The lack of a specific treatment for COVID-19 brought to mind the possibility of passive immunotherapy, first through the transfusion of convalescent donor plasma, and then the plasma of vaccinated individuals. The purpose of such therapy is to introduce covid antibodies into the recipient's blood to neutralize the virus. At the same time, the question remains about the effectiveness of this treatment method in patients in serious and extremely serious condition in the intensive care unit of the COVID center. According to various studies, anticovid plasma is suitable for use in patients at the initial stages of the disease and in the presence of immunodeficiency in the patient. At the same time, the overall mortality in the intensive care unit and intensive care among severe and extremely severe patients may not decrease.